ERBB4
ENSG00000178568
Target class
Kinase
Chromosome
2
Approved drugs
6
Clinical candidates (approved and in development)
13
- Approved drugs
- 6
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- No
- Target name
- ERBB4
- Gene name
- Erb-b2 receptor tyrosine kinase 4
- Gene symbol
- ERBB4
- Protein name
- Receptor tyrosine-protein kinase erbB-4 (EC 2.7.10.1) (Proto-oncogene-like protein c-ErbB-4) (Tyrosine kinase-type cell surface receptor HER4) (p180erbB4) [Cleaved into: ERBB4 intracellular domain (4ICD) (E4ICD) (s80HER4)]
- ALS19
- HER4
- Gene biotype
- Protein coding
- Gene family
- Erb-b2 receptor tyrosine kinases|MicroRNA protein coding host genes
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 26
- Highest tissue expression
- 9.09
- Tissue specificity (Gini)
- 0.629
- Tissue specificity (tau)
- 0.765
- KEGG gene identifiers
- hsa:2066
- Protein interaction confidence
- 0.842523
- Protein interaction partners
- 107
- End position
- 212538841
- Start position
- 211375717
- Chromosome
- 2
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein . Note=In response to NRG1 treatment, the activated receptor is internalized.
- SUBCELLULAR LOCATION: [ERBB4 intracellular domain]: Nucleus . Mitochondrion . Note=Following proteolytical processing E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus.
- PubMed 10348342
- PubMed 12807903
- PubMed 15534001
- PubMed 16251361
- PubMed 16778220
- PubMed 16837552
- PubMed 17486069
- PubMed 17638867
- PubMed 19193720
- PubMed 20858735
- PubMed 8383326
- PubMed 9334263
- Tissue specificity (tau)
- 0.764576
- Expression inequality (Gini)
- 0.628567
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 9.09
- Artery - Aorta
- 8.63
- Brain - Anterior cingulate cortex (BA24)
- 8.62
- Brain - Frontal Cortex (BA9)
- 7.97
- Brain - Caudate (basal ganglia)
- 7.56
Expression in transcripts per million
- Brain - Cerebellar Hemisphere9.09
- Artery - Aorta8.63
- Brain - Anterior cingulate cortex (BA24)8.62
- Brain - Frontal Cortex (BA9)7.97
- Brain - Caudate (basal ganglia)7.56
- Brain - Cerebellum7
- Brain - Nucleus accumbens (basal ganglia)6.66
- Brain - Amygdala6.25
- Brain - Putamen (basal ganglia)5.55
- Brain - Cortex5.48
- Testis5.02
- Brain - Hypothalamus4.39
- Brain - Hippocampus4.03
- Brain - Substantia nigra4.03
- Kidney - Medulla3.57
- Minor Salivary Gland2.82
- Artery - Tibial2.75
- Pituitary2.4
- Brain - Spinal cord (cervical c-1)2.38
- Thyroid2.19
- Heart - Atrial Appendage2.17
- Kidney - Cortex2.12
- Artery - Coronary1.94
- Breast - Mammary Tissue1.44
- Fallopian Tube1.29
And 29 more, listed on the interactive page.
- GO:0001934
- GO:0007165
- GO:0007169
- GO:0007595
- GO:0008284
- GO:0008285
- GO:0016477
- GO:0018108
- GO:0038130
- GO:0038138
- GO:0042531
- GO:0043653
- GO:0045893
- GO:0046427
- GO:0046777
- GO:0070374
- GO:0005576
- GO:0005634
- GO:0005654
- GO:0005739
- GO:0005759
- GO:0005829
- GO:0005886
- GO:0016323
- GO:0043235
- GO:0000976
- GO:0004713
- GO:0004714
- GO:0005154
- GO:0005515
- GO:0038131
- GO:0042803
Related records
Trials (1,075)
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
- A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
- A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
- A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
- A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Drugs (24)
- AC-480 Receptor protein-tyrosine kinase erbB-4 inhibitor
- Acalabrutinib
- AEE-788
- Afatinib Receptor protein-tyrosine kinase erbB-4 inhibitor
- Afatinib dimaleate Receptor protein-tyrosine kinase erbB-4 inhibitor
- Allitinib
- BMS-690514 Receptor protein-tyrosine kinase erbB-4 inhibitor
- Canertinib Receptor protein-tyrosine kinase erbB-4 inhibitor
- Canertinib dihydrochloride Receptor protein-tyrosine kinase erbB-4 inhibitor
- Dacomitinib Receptor protein-tyrosine kinase erbB-4 inhibitor
- Dacomitinib anhydrous Receptor protein-tyrosine kinase erbB-4 inhibitor
- Ibrutinib
- JNJ-26483327 Receptor protein-tyrosine kinase erbB-4 inhibitor
- KBP5209 Epidermal growth factor receptor inhibitor
- Neratinib Receptor protein-tyrosine kinase erbB-4 inhibitor
- Neratinib maleate Receptor protein-tyrosine kinase erbB-4 inhibitor
- Poziotinib Epidermal growth factor receptor inhibitor
- Poziotinib hydrochloride Epidermal growth factor receptor inhibitor
- Tarloxotinib Epidermal growth factor receptor inhibitor
- Tarloxotinib bromide Epidermal growth factor receptor inhibitor